Patent · US Active

Antibody molecules

US12247074B2 · kind B2 · utility

0Cited by
20References
21Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 12, 2019
Grant dateMar 11, 2025
Priority date
Expiry dateJul 7, 2042

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure, in some aspects, provides antibody molecules, or antigen-binding fragments thereof capable of binding specifically to PD-L1. The present disclosure further provides antibody molecules, or antigen-binding fragments thereof capable of binding specifically to PD-L1 and a second antigen-binding site. Methods of making and/or using such antibody molecules or antigen bending fragments are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.